Invasive Node-Positive Breast Cancer

The Oncotype DX® Breast Recurrence Score has been clinically validated in multiple large cohorts of early stage ER+ breast cancer patients with node-negative and node-positive disease. The following summarizes the validation, clinical utility, and health economic evidence in node-positive patient populations.

  • The Oncotype DX Breast Recurrence Score validation has been demonstrated and supported in multiple large studies in node-positive breast cancer patients: Eastern Cooperative Oncology Group (ECOG) 2197, Southwest Oncology Group (SWOG) 8814, Arimidex, Tamoxifen Alone or in Combination (ATAC), National Surgical Adjuvant Breast and Bowel Project (NSABP) B-28, and Programme Action Concertée Sein (PACS) 01
  • The Oncotype DX Breast Recurrence Score provides useful information for newly diagnosed, estrogen receptor-positive, node-positive patients regarding their risk of distant recurrence and anticipated benefit of chemotherapy.
  • The Breast Recurrence Score result provides direct insight to individual tumor biology and guides adjuvant treatment decision-making for patients with estrogen receptor-positive, node-positive breast cancer, yielding an overall reduction in chemotherapy recommendations.


Next: Clinical Impact and Economic Studies